Source of Third-party testing
Page source·read-only·revision 39
Editing is disabled on this mirror. This is the page source as of revision 39, saved by BetaCellBoyd on 19 July 2026. It is shown so that the markup behind the rendered article can be read and reused under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).
7,489 bytes · 82 lines · 4 top-level sections · 4 defined citations. The markup grammar is documented at Project:Manual of style.
{{Infobox concept
| name = Third-party testing
| subtitle = Quality assurance
| image = coa-sheet.svg
| caption = An independent report differs from a supplier certificate principally in who commissioned it.
| Also called = Independent testing, buyer-commissioned testing
| Commissioned by = The purchaser, not the supplier
| Reported to = The submitter
<!-- What it can establish -->
| Identity = If mass or sequence confirmation is included
| Purity of the sample = By [[Area percent purity|area percent]] on the material submitted
| Content = Only if [[Peptide content|content]] is determined
<!-- What it cannot establish -->
| Lot representativeness = Without [[Blind sampling|blind sampling]]
| Provenance = Without a [[Chain of custody|chain of custody]]
}}
{{hatnote|For the document a supplier issues about its own material, see [[Certificate of analysis]].}}
'''Third-party testing''' is the analysis of a material by a laboratory that is independent of the supplier and of the manufacturer, commissioned by the purchaser and reported to the purchaser. It is distinguished from a supplier's own [[Certificate of analysis|certificate of analysis]] not by the analytical methods used, which may be identical, but by who paid for the work and who receives the result.{{r|usp1503}}
The distinction matters because the incentive structure differs. A supplier commissioning analysis of its own material controls which sample is submitted, whether an unfavourable result is published, and how the result is described. A purchaser commissioning analysis of material already received controls none of those things but is testing a sample of unknown representativeness.{{r|reports}}
Independent testing is therefore evidence about a sample rather than about a lot, and about a lot rather than about a supplier. Treating a single favourable independent report as a general statement about an organisation is the commonest error made with these documents.{{r|reports}}
== What an independent report establishes ==
An independent report establishes, at most, the properties of the material that reached the laboratory. Whether those properties can be extended to the lot the material came from depends on how the sample was drawn, and whether they can be extended to the supplier depends on how many lots have been examined and over what period.{{r|usp1503}}
Three separate questions are involved and are routinely collapsed into one.
# ''Is this sample what it claims to be?'' Answered by identity determination — [[Mass spectrometry|mass confirmation]] against the calculated mass, ideally with sequence-level confirmation. A purity figure alone does not answer it.
# ''How pure is this sample?'' Answered by chromatographic purity, which is an area-normalised figure and not a mass.
# ''How much active substance is in the vial?'' Answered only by [[Peptide content|peptide content]] together with a water determination and a fill mass. Purity does not answer it.
A report addressing only the second of these — which many do — leaves the first and third open. A specification is judged by which attributes it covers, not by how favourable the covered ones look.{{r|ich_q6b}}
== Sampling and representativeness ==
A sample submitted by a purchaser is a sample of one vial from one order. If a supplier ships from a single lot, the vial may fairly represent it; if a shipment draws from several lots, or if the vial submitted was selected rather than drawn at random, it does not.{{r|reports}}
[[Blind sampling|Blind sampling]] — in which the laboratory does not know the origin of the sample and the supplier does not know a sample has been drawn — removes one class of bias. A [[Chain of custody|chain of custody]] documenting who held the material between purchase and analysis removes another. Reports that arise from neither are still informative, but they are informative about a narrower thing than they appear to be.
The self-selection problem operates at the level of what gets reported at all. Purchasers who commission testing are not a random sample of purchasers, and results that are published are not a random sample of results obtained. This wiki's own community tally is subject to both effects and says so.{{r|reports}}
== Services referenced on this wiki ==
Four services are referred to throughout the site's body copy, and each has an article: [[Janoshik Analytical]], [[Medutest]], [[PeptideMeter]] and [[VendorInvestigate]]. They differ in what they do — two are analytical laboratories, one is a results database, one is a documentary review service — and are not interchangeable.
| Service | What it produces |
|---|---|
| [[Janoshik Analytical]] | Analytical report with released chromatogram |
| [[Medutest]] | Analytical report on submitted material |
| [[PeptideMeter]] | Aggregated public database of submitted results |
| [[VendorInvestigate]] | Documentary and supply-chain review |
A "PeptideMeter figure" and a "Janoshik result" are therefore not the same kind of object: one is an aggregate over submissions, the other a determination on a sample. Citing them as though they were commensurable is a category error that appears frequently in secondary discussion.{{r|reports}}
== Reading a report against a certificate ==
Where an independent report and a supplier certificate cover the same lot, agreement between them is often presented as validation. It is weaker than that: it establishes that two measurements of the same material agreed, which is expected if both laboratories are competent, and says nothing about whether the material is representative.{{r|usp1503}}
Disagreement is more informative than agreement, but only if the two determinations are comparable. Two [[Area percent purity|area percent]] figures obtained on different gradients, different columns and different detection wavelengths are not directly comparable, and a difference of a few tenths of a percentage point is within the repeatability of most peptide purity methods. See [[Analytical method validation]].
The practical consequence is that a certificate which does not name its column, gradient and wavelength cannot be compared with anything. Method transparency is what makes a number checkable, and it is a more useful criterion for reading a document than the number itself.{{r|usp1503}} Laboratory competence standards make the same point from the other side: a result is reportable only with the method and conditions that produced it.{{r|iso17025}}
== References ==
{{reflist}}
<ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref>
<ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref>
<ref name="ich_q6b">International Council for Harmonisation, ''Q6B: Specifications — Test Procedures and Acceptance Criteria for Biotechnological/Biological Products'' (1999).</ref>
<ref name="iso17025">ISO/IEC 17025:2017, ''General requirements for the competence of testing and calibration laboratories''.</ref>
== See also ==
* [[Certificate of analysis]]
* [[Blind sampling]]
* [[Chain of custody]]
* [[Janoshik Analytical]]
* [[PeptideMeter]]
* [[Area percent purity]]
* [[Peptide content]]
{{DEFAULTSORT:Third-party testing}}
[[Category:Independent testing services]]
[[Category:Testing methodology]]
[[Category:Certificates of analysis]]
Templates in this source are rendered by the site generator: {{r|id}} becomes a numbered citation, {{figure|key|caption}} a framed diagram, {{main|Title}} a cross-reference line.